Vivos Therapeutics, Inc. has filed a definitive proxy statement with the SEC, marking an important step in its corporate governance process. The filing, dated October 29, 2026, outlines crucial matters that will be put to a vote by shareholders. This event is significant as it reflects the company's commitment to transparency and shareholder engagement.

Vivos Therapeutics, Inc. operates in the surgical and medical instruments and apparatus sector, identified by the SIC code 3841. The company is listed on the Nasdaq under the ticker symbol VVOS and is classified as a smaller reporting company. Vivos has been active in the market with several recent filings, including its latest proxy statement.

The definitive proxy statement includes details regarding executive compensation, stock awards, and other governance matters that shareholders will need to consider. While the filing does not provide specific figures or proposals, it emphasizes the importance of shareholder participation in the decision-making process.

This filing could impact various stakeholders, including shareholders, executives, and employees. The decisions made during the upcoming vote may influence the company's operational strategies and financial performance. Additionally, as Vivos navigates these governance issues, it may set a precedent for other companies within the surgical and medical instruments industry.

Looking ahead, Vivos Therapeutics may provide further updates or additional filings as the shareholder meeting approaches. The filing does not specify what happens next, but it underscores the company's ongoing efforts to align its governance practices with shareholder interests.